Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,354.00 -10.73 (-0.79%)

Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now? ↗

Today 15:35 EST

Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.

Via The Motley Fool

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials ↗

November 07, 2026

Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.

Via The Motley Fool

Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy? ↗

November 07, 2026

The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.

Via The Motley Fool

IYH and XBI: Two Distinct Paths to Investing in Healthcare ↗

November 07, 2026

XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.

Via The Motley Fool

Topics ETFs

Certified PEP MEX Expands Its Reach in Mexico With Two New Research Peptide Websites

November 07, 2026

Via Press Release Distribution Service

Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence ↗

November 06, 2026

Eli Lilly could thrive even as competition in the weight-loss market intensifies.

Via The Motley Fool

Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly ↗

November 06, 2026

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.

Via Investor's Business Daily

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

November 06, 2026

From Hims & Hers

Via Business Wire

2 Growth Stocks to Buy in November Without Any Hesitation ↗

November 05, 2026

They have both outperformed the broader equity market over the long run.

Via The Motley Fool

Here's the 1 Stock I'd Most Want to Buy If the Market Crashes ↗

November 05, 2026

Investors should look to defensive stocks in the healthcare sector during a major market correction.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

OPKO Health (OPK) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Sale of BioReference brings $722 million in cash as the company narrows its focus to biotech.

Via The Motley Fool

Topics Earnings

These 6 Stocks Make Up a Big Share of the S&P 500 ↗

November 05, 2026

Six tech stocks make up nearly a third of the S&P 500. Here's how AI spending is shaping each one's results.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Elanco (ELAN) reports earnings tomorrow: what to expect

November 04, 2026

Animal health company Elanco (NYSE:ELAN) will be reporting results this Friday before market hours. Here’s what to expect. Elanco beat analysts’ revenue expe...

Via StockStory

Topics Artificial Intelligence

The Nasdaq-100 Is Outperforming Nvidia, Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla This Year. Here's My Favorite Low-Cost ETF to Buy the Dip. ↗

November 04, 2026

Many megacap growth stocks are underperforming the major indexes this year.

Via The Motley Fool

Topics ETFs Stocks

If the S&P 500 Falls 20%, Here's the 1 ETF I'd Buy Hand Over Fist ↗

November 04, 2026

Some individual stocks keep falling. The broader U.S. stock market has always bounced back.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. ↗

November 04, 2026

Viking aims to enter the weight loss drug market.

Via The Motley Fool

What to expect from ANI Pharmaceuticals’s (ANIP) Q3 earnings

November 03, 2026

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Thursday before market open. Here’s what investors should ...

Via StockStory

Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow

November 03, 2026

Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...

Via StockStory

Topics Artificial Intelligence

Viatris (VTRS) Q3 earnings report preview: what to look for

November 03, 2026

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what investors should know. Viatris be...

Via StockStory

Topics Artificial Intelligence

Amphastar Pharmaceuticals (AMPH) to report earnings tomorrow: here is what to expect

November 03, 2026

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market close. Here’s what to look for. Amphastar ...

Via StockStory

Collegium Pharmaceutical (COLL) Q3 earnings: what to expect

November 03, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should...

Via StockStory

Topics Artificial Intelligence

3 Dirt Cheap Dividend Stocks to Buy in November 2026 ↗

November 03, 2026

These high-yielding stocks pay up to 7.4% in dividends.

Via The Motley Fool

Topics Economy

Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion

November 03, 2026

Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets

From FN Media

Via GlobeNewswire

Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion

November 03, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Retatrutide Research Draws Attention in Costa Rica as Demand for Reliable Scientific Information Grows

November 03, 2026

Via Press Release Distribution Service

Phibro Animal Health (PAHC) reports earnings tomorrow: what to expect

November 02, 2026

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be announcing earnings results this Wednesday after market hours. Here’s what inv...

Via StockStory

Eli Lilly Stock: Is It Still a Buy at $1,400? ↗

November 02, 2026

The company just released some incredible quarterly results, but its valuation is also fairly high.

Via The Motley Fool

Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy? ↗

November 02, 2026

The drugmaker continues its impressive run.

Via The Motley Fool

GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge? ↗

November 02, 2026

Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to...

Via MarketBeat

Topics ETFs

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗

November 02, 2026

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.